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Periodontal disease, as a polymicrobial disease, is globally endemic as well as being a global epidemic. It is the leading cause 
for tooth loss in the adult population and has been positively related to life-threatening systemic diseases such as atheroscle-
rosis and diabetes. As a result, it is clear that more sophisticated therapeutic modalities need to be developed, which may in-
clude vaccines. Up to now, however, no periodontal vaccine trial has been successful in satisfying all the requirements; to pre-
vent the colonization of a multiple pathogenic biofilm in the subgingival area, to elicit a high level of effector molecules such 
as immunoglobulin sufficient to opsonize and phagocytose the invading organisms, to suppress the induced alveolar bone 
loss, or to stimulate helper T-cell polarization that exerts cytokine functions optimal for protection against bacteria and tissue 
destruction. This article reviews all the vaccine trials so as to construct a more sophisticated strategy which may be relevant in 
the future. As an innovative strategy to circumvent these barriers, vaccine trials to stimulate antigen-specific T-cells polarized 
toward helper T-cells with a regulatory phenotype (Tregs, CD4+, CD25+, FoxP3+) have also been introduced. Targeting not only 
a single pathogen, but polymicrobial organisms, and targeting not only periodontal disease, but also periodontal disease- 
triggered systemic disease could be a feasible goal.
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Review
PERIODONTITIS AS A DISEASE ENTITY
Periodontal disease refers to the processes of destruction of 
the peri-tooth structures that support the teeth. These are com-
posed of the gingiva, the periodontal ligament, the cemen-
tum, and the alveolar bone. The chronic destruction of these 
supporting tissues leads to the eventual loss of teeth and hence 
partial or full edentulism. Epidemiological studies reveal that 
more than two-thirds of the world’s population suffers from 
one of the chronic forms of periodontal disease. Recent rec-
ognition of the importance of periodontal disease and its im-
pact on the perpetuation and management of systemic dis-
eases calls for a global effort to control periodontal disease.
Two forms of periodontitis have been proposed: One is 
chronic periodontitis (previously termed “adult periodonti-
tis”), which affects primarily the adult population who are > 35 
years of age. This type of periodontitis is frequently associat-
ed with an elevated number and frequency of Porphyromonas 
(P.) gingivalis, Treponema (T.) denticola, and Tanerella (T.) for-
sythia detected in the subgingival microbial community. 
Contributing local factors consisting of conspicuous dental 
plaque, calculus, root surface accretions, and overhanging res-
torations are closely associated quantitatively or qualitatively 
with disease expression. The other form, aggressive periodon-
titis (previously referred to as “early-onset periodontitis”), is 
associated with young adults (< 35 years of age) and is charac-
terized by rapid destruction with minimal signs of gingival 
inflammation. Aggregatibacter (A.) actinomycetemcomitans 
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(formerly Actinobacillus actinomycetemcomitans) is defined as 
the predominant cultivable organism in localized afflicted 
sites, whereas P. gingivalis, Prevotella (P.) intermedia and Capno-
cytophaga (C.) sputigena are frequently isolated in the general-
ized form. The aggressive forms of periodontitis suggest a 
genetic predisposition with a minimal number of noticeable 
local factors. The American Academy of Periodontology 
(1999) proposed disregarding the association of age with ei-
ther form of the disease, since both can affect young and old 
populations regardless of age. Other periodontal diseases in-
clude gingival diseases, necrotizing periodontal diseases, ab-
scesses, developmental and acquired forms of periodontal 
diseases, and combined endodontic-periodontal lesions.
PERIODONTITIS AS A POLYMICROBIAL  
INFECTION
Traditional concepts of the etiology and initiation of peri-
odontal disease stem from the observation that gingival in-
flammation ensues from the sequential and quantitative mi-
crobial load accumulating in the gingival sulcus as an orga-
nized biofilm known as bacterial plaque. The current concept 
emerges from extensive research findings on the polymicro-
bial nature of the associated biofilm. This has led to the no-
tion that biofilm quality is the critical factor in the pathogen-
esis of periodontal disease. Indeed it is now thought that peri-
odontal disease is a specifically combined infectionof polymi-
crobial Gram-negative anaerobic bacteria, including P. gingi-
valis, T. denticola and T. forsythia, and A. actinomycetemcomitans, 
all of which have been proposed as predominant pathogens, 
exclusively or synergistically with other bacteria, including P. 
intermedia, Campylobacter (C.) rectus, Fusobacterium (F.) nuclea-
tum, and herpes virus.
Although periodontal diseases are primarily initiated and 
perpetuated by mixed biofilm (possibly also including virus-
es), other factors including host-associated factors, genetic 
predisposition, immune dysfunction, and environmental fac-
tors can exacerbate the disease. Thus, a combined strategy, 
targeting both specific pathogenic species and the host im-
mune response would have to be adopted for the sophisticat-
ed management of the compromised subject.
EMERGING CONCEPTS REGARDING  
VACCINE DEVELOPMENT
Three emerging concepts of periodontal disease may influ-
ence the development of a sophisticated vaccine to eradicate 
or alleviate the disease burden. The first is that periodontal 
disease is a polymicrobial infection. The second is that it is a 
major cause of adult tooth loss worldwide. The third is that 
periodontal disease contributes to the perpetuation of sys-
temic diseases of critical importance (atherosclerosis, diabetes 
mellitus, etc.).
Ever since the introduction of the smallpox vaccine by Jen-
ner in 1798, antigens of infectious pathogenic bacteria and vi-
ruses have been the targets for a variety of vaccines against a 
number of infectious diseases. Within this context, vaccine 
strategy has been based on prevention of disease and less so 
on their treatment. Thus, most vaccines target one or multi-
ple antigenic components of mono-infecting bacteria or vi-
ruses. At the same time, most experiments on immunization 
of periodontitis, despite its poly-infectious nature, have been 
directed toward a very limited number of antigenic compo-
nents of a single specific pathogen, either P. gingivalis or A. 
actinomycetemcomitans. 
THE SIGNIFICANCE OF PERIODONTAL  
VACCINE DEVELOPMENT
The demanding primary role of any periodontal vaccine 
would be to eradicate the global periodontal disease burden 
with the ultimate purpose of lowering periodontal disease-
associated morbidity in humans. The role of any vaccine, how-
ever, should also be seen within the context of changes in life-
style. The vaccine effect should be seen to enhance the feasi-
bility of maintaining oral health and to maximize retention 
of the natural dentition, thus minimizing the need for pros-
thetic or implant restorations in the oral cavity. The so-called 
“healthy gum-healthy body” lifestyle could also lessen the 
economic burden incurred by restorative dental treatment. 
Moreover, recent novel findings linking periodontitis and 
systemic health concerns (atherosclerosis, diabetes mellitus, 
pre-term low-weight birth, rheumatoid arthritis, etc.) would 
suggest that prevention or treatment of periodontal diseases 
is fundamental to the effective management of atherosclero-
sis, uncontrolled diabetes, and low-weight pre-term birth or 
preeclampsia.
BASIC TENETS IN DEVELOPING STRATEGIES 
FOR PERIODONTITIS VACCINES
Despite the considerable numbers of cultivable microorgan-
isms identifiable in the subgingival niche, researchers have 
narrowed the number of putative periodontal pathogens 
down to six or seven, P. gingivalis, T. denticola and T. forsythia, 
A. actinomycetemcomitans, P. intermedia, C. rectus, and F. nu-
cleatum, which are predominantly cultivated in sites demon-
strating disease activity. Socransky et al. [1] proposed the Red 
complex, namely P. gingivalis, T. denticola and T. forsythus, as 
the predominant disease-associated organisms. Later P. inter-Journal of Periodontal
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media, Dialister pneumosintes, Eubacterium nodatum, C. rectus, 
and F. nucleatum, were also added as putative periodontal 
pathogens [2]. Viruses (herpes virus) and their interaction with 
periodontal pathogenic bacteria have also been suggested to 
be periodontal pathogens with the recent advent of molecu-
lar diagnostic techniques [3-6]. In addition, aggressive peri-
odontitis patients may not only harbor the distinct bacterial 
species associated with disease activity, but may also harbor A. 
actinomycetemcomitans, especially in a localized form.
Most immunization approaches, both active and passive, 
against periodontitis have been focused on P. gingivalis and A. 
actinomycetemcomitans. The target antigens have evolved 
from the whole organism to specific virulence factors (struc-
tural components or secreted products) that could confer im-
munity against colonization or the virulent activity of putative 
periodontal pathogens. 
Vaccine testing animal systems have ranged from mice and 
rats to dogs and nonhuman primates. In order to evaluate vac-
cine efficacy in terms of the human immune system, a sophis-
ticated humanized mouse system has been introduced with 
the adoptive transfer of human peripheral blood lymphocytes 
(PBLs) into a severe combined immunodeficiency (SCID) 
mouse system as well as into a non-obese diabetes (NOD)-scid 
mouse model. However, due to frequent episodes of leakiness 
of these mouse systems, a more stringent model with low 
leakiness has now been developed: NOD.CB17-prkdc
scid/J.
IMMUNIZATION AGAINST PORPHYROMONAS 
GINGIVALIS
As noted above, P. gingivalis has been implicated as a major 
periodontopathogen in human periodontitis [7]. In this con-
text, it has developed a variety of survival strategies enabling 
it to evade host defense mechanisms. Virulence components 
of the bacterial cell include cysteine proteases, fimbriae, capsu-
lar polysaccharide (CPS), lipopolysaccharide, and outer mem-
brane vesicles [8].
Both heat- and formalin-killed P. gingivalis whole cell vac-
cines, either alone or conjugated with syntax adjuvant, have 
been reported to inhibit the progression of periodontal dis-
ease and to elevate serum immunoglobulin G (IgG) and IgA 
titers that demonstrated opsonophagocytic capability in non-
human primates [9-11]. Further, a recent study in mice immu-
nized with heat-killed P. gingivalis reported the induction of P. 
gingivalis-specific IgG with optimal levels of opsonization of the 
microorganism and the prevention of alveolar bone loss [12].
These studies, however, lack evidence of long-term immune 
memory and cell-mediated immune responses that would al-
low them to be adopted as a feasible vaccine strategy.
Gingipain, the term adopted for P. gingivalis specific cyste-
ine proteases, represents one of the major pathogenic viru-
lence factors for this organism. It consists of two components: 
gingipain R (RgpA and RgpB) that cleaves proteins at arginine 
residues, and gingipain K (porphypain 2, Kgp) that cleaves pro-
teins at lysine residues. As a result, it has drawn considerable 
interest as a candidate target antigen for periodontal vaccine 
development [13].
Both RgpA and Kgp (but not RgpB) have a hemagglutinin 
domain that is essential for the adherence to erythrocytes, 
while the catalytic domain (in RgpA, RgpB, and Kgp) plays an 
important role in the evasion of the host defense system by 
degrading immunoglobulins and complement proteins and 
by disturbing the functions of neutrophils [14,15]. Spurred by 
these findings, an active immunization program using puri-
fied P. gingivalis cysteine protease (porphypain-2) has been 
carried out, which resulted in a significantly elevated specific 
IgG antibody response that suppressed P. gingivalis-induced 
bone loss in Macaca (M.) fascicularis [16].
However, with repeated immunization, the authors realized 
that only animals immunized with RgpA produced hemag-
glutinin domain-specific antibodies that contributed to the 
prevention of P. gingivalis-mediated periodontal disease [17]. 
Furthermore, immunization with the RgpA-Kgp proteinase-
adhesin complexes of P. gingivalis protected against periodon-
tal bone loss by eliciting a high titer of serum IgG2a response 
in the rat. This approach seems to open a new venue for fur-
ther trials to pursue.
As P. gingivalis requires the hemagglutinin 2 (HA2) domain 
for survival through heme acquisition, an HA2 domain-based 
vaccine (rHA2) was administered to rats resulting in signifi-
cantly enhanced IgG levels and some protection against ex-
perimental periodontitis. However, one clinical trial reported 
that periodontal patients demonstrated high IgG titers to the 
HA domain but not to the catalytic domain, because the cat-
alytic domain is not exposed on the gingipain complex [18]. 
Furthermore, it is assumed that insufficient levels of human 
antibody to the catalytic subunits of RgpA and RgpB may be 
responsible for development of periodontitis, thus suggest-
ing the need for inclusion of the catalytic subunit in vaccine 
design. Interestingly, a mouse immunization study, utilizing 
a synthetic peptide representing the N-terminus of the RgpA 
catalytic domain, RgpA45, coupled to an oligolysine, reported 
an increased level of IgG with protective capacity against P. 
gingivalis. Additional studies performed in murine models in-
corporating peptides of the catalytic domains or DNA vaccine 
encoding the subunit have strengthened the importance of 
inclusion of the catalytic subunit in the vaccine regimen by 
demonstrating the protective function of the anti-catalytic 
domain antibodies against P. gingivalis infection [19]. 
The fimbriae of P. gingivalis, which consist of one major Journal of Periodontal
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fimbriae and two minor fimbriae of 67 kDa and 72 kDa, re-
spectively, are virulence factors in the pathogenesis of peri-
odontal disease. When rats were parenteraly immunized with 
purified 43-kDa fimbrial protein, the resultant fimbrial A-spe-
cific antibodies in serum and saliva gave a satisfactory level of 
protection against P. gingivalis-induced alveolar bone loss [20].
Intranasal administration of P. gingivalis fimbrial antigen 
with recombinant cholera toxin B subunit also induced a sig-
nificant immune response (fimbrial-specific secretory IgA-
sIgA) in mice, which could reduce P. gingivalis-mediated al-
veolar bone loss. It is also possible that this mucosal immuni-
zation resulted in peripheral tolerance and hence a reduced 
inflammatory response and alveolar bone loss. However, it 
has further been demonstrated that immunization with 43-
kDa fimbrillin polymer of P. gingivalis did not show satisfac-
tory levels of protection against all strains of P. gingivalis test-
ed [21]. The feasibility of this fimbrial protein of P. gingivalis 
as a vaccine candidate antigen may therefore be dependent 
on its effectiveness in protecting against all the P. gingivalis 
strains.
A conjugate vaccine incorporating both fimbriae and P. gin-
givalis CPS, has been introduced in a study that led to the pro-
duction of a high IgG response and which was effective in 
protecting against P. gingivalis infection [22]. However, in this 
study it was not clear whether the protection came from the 
CPS or fimbriae. CPS, by virtue of its encapsulation and anti-
genic shift, constitutes a robust strategy for P. gingivalis sur-
vival against opsonophagocytic activity. Due to its poor T-cell 
stimulating ability, however, CPS of other Gram-negative bac-
teria is usually conjugated to a protein antigen (for stimulat-
ing helper T-cells) in many vaccine trials in infectious diseas-
es, such as pneumonia and meningitis. More recently, P. gin-
givalis CPS alone has nevertheless, been used as an immuno-
gen, and it has been reported to result in an elevated produc-
tion of serum IgG and IgM that provided protection against P. 
gingivalis-induced bone loss [23].
PASSIVE IMMUNIZATION AGAINST PORPHY-
ROMONAS GINGIVALIS
In terms of an anti-infective scheme, monoclonal antibod-
ies targeting these antigenic molecules of P. gingivalis could 
potentially be adopted as a sophisticated mode of immuno-
therapy. 
Outer membrane proteins (OMPs) are important coaggre-
gation factors and as such are major colonization factors of P. 
gingivalis [24-26]. Since IgG specific for the 40 kDa-OMP in-
hibited coaggregation of P. gingivalis vesicles and S. gordonii, 
it could conceivably be used to prevent P. gingivalis infection 
[27]. In support of this, a panel of mouse monoclonal anti-
bodies (mAb) against purified r40-kDa OMP specifically in-
hibited the coaggregation of A. naeslundii with several strains 
of P. gingivalis [28]. Furthermore, an IgG2 human mAb (HAB-
OMP1) has been shown to significantly inhibit the coaggre-
gation activity of P. gingivalis vesicles with A. naeslundii [29]. 
Most recently, a multi-centered genomic analysis of P. gingi-
valis has reported that recombinant OMP antigens PG32 and 
PG33, both known to play an important role in bacterial growth, 
coaggregation with other bacteria, and transcription, are po-
tential vaccine candidates [30].
Erythrocyte-derived protoheme is known to be one of the 
absolute requirements for the persistent growth of P. gingi-
valis [31]. It is the hemagglutinins of P. gingivalis that facilitate 
its attachment to the erythrocyte cell surface, allowing it to 
access protoheme. Hence, applying an mAb against the 
hemagglutinin could be seen as a potential passive immuni-
zation strategy against the persistence of P. gingivalis in the 
subgingival niche.
Based on this concept, local passive immunization with 
rabbit antiserum against P. gingivalis hemagglutinin has in 
fact resulted in a reduced colonization by exogenous P. gingi-
valis in the subgingival area over a 3-week period [32]. In ad-
dition, localized administration of a P. gingivalis-specific 
mAb (MAb61BG1.3) at severely infected subgingival sites has 
been shown to significantly reduce subsequent P. gingivalis 
recolonization for up to 9 months in periodontal patients [33]. 
It was subsequently shown that the mechanism by which 
MAb61BG1.3 inhibited the adhesion of P. gingivalis to the re-
ceptors on erythrocytes was due to its ability to block the hem-
agglutinating protease [34].
As an advanced step forward in this approach, a single-chain 
variable fragment (scFv) mAb that recognized the 43-and 49-
kDa proteins of P. gingivalis vesicles was prepared [35]. This scFv 
mAb was found to inhibit vesicle-associated hemagglutinating 
activity in a dose-dependent manner. Also, a monoclonal anti-
body using P. gingivalis vesicles as the immunogen (MAb-Pg-
vc) was shown to inhibit vesicle-associated hemagglutinating 
activity when incubated with rabbit erythrocytes [36].
Recently, human lymphocytes, isolated from a donor with a 
high antibody titer against a recombinant 130 kDa hemagglu-
tinin domain (r130k HMGD), were immortalized with Epstein-
Barr virus, and specific antibody-producing B cells were es-
tablished resulting in a human mAb (59). The human mAb 
HMGD1 significantly inhibited the hemagglutinating activi-
ty of P. gingivalis vesicles in a dose-dependent manner and 
may prove to be a useful tool for passive immunization against 
periodontal disease [37]. Interestingly, in a novel introduction 
of XenoMouse technology, Shibata et al. [38] constructed an 
IgG2 Xeno-monoclonal antibody against the recombinant 
130-kDa hemagglutinin domain of P. gingivalis and demon-Journal of Periodontal
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strated a significant inhibition of hemagglutination by P. gin-
givalis and its vesicles [38].
These results support the hypothesis that a monoclonal an-
tibody specific to a bacterial antigen could prove to be an ef-
fective mode of passive immunization against P. gingivalis 
and possibly other periodontopathic bacteria.
IMMUNIZATION AGAINST AGGREGATIBACTER 
ACTINOMYCETEMCOMITANS
A. actinomycetemcomitans is considered another important 
pathogen in human periodontal disease, especially in the lo-
calized form of aggressive periodontitis. 
Harano et al. [39] prepared an antiserum against a synthetic 
fimbrial peptide of A. actinomycetemcomitans and found that it 
blocked the adhesion of the organism to saliva-coated hy-
droxyapatite beads, to buccal epithelial cells, and to a fibroblast 
cell line. Also, subcutaneous and intranasal immunization of 
mice with capsular serotype b-specific polysaccharide anti-
gen of A. actinomycetemcomitans resulted in a specific anti-
body that efficiently opsonized the organism [40].
Furthermore, when mice were immunized with anti surface-
associated material from A. actinomycetemcomitans, it yielded a 
raised protective opsonic antibody response and rapid heal-
ing of the primary lesions following a challenge with live A. 
actinomycetemcomitans [41]. However, relatively few studies 
have been conducted on developing vaccines against A. acti-
nomycetemcomitans.
REGULATION OF THE IMMUNE RESPONSE 
TO THE POLYMICROBIAL BIOFILM: A VAC-
CINE PERSPECTIVE
The subgingival microbial community demonstrates the 
distinctive ecologic features characteristic of a polymicrobial 
biofilm world with both synergistic and antagonistic commu-
nications among the complex microbial organisms. When the 
polymicrobial biofilm mass becomes mature and thicker with 
continuous colonization by the early, intermediate, and late 
colonizers, it demonstrates both quorum sensing [42] and 
genetic communication through pathogenicity islands [43].
The host immune response to this biofilm is modulated by 
the array of different microbial challenges including both spe-
cific and cross-reactive antigens. This phenomenon then re-
sults in the recruitment of diverse antigen-specific B- and T-
lymphocytes, which may in turn demonstrate a wide spectrum 
of poly-reactivity [44-47].
Two different independent research groups have evaluated 
immune modulation by immunizing F. nucleatum prior to 
subsequent immunization of P. gingivalis. When mice were 
immunized with F. nucleatum prior to P. gingivalis, a signifi-
cantly decreased antibody response to P. gingivalis was ob-
served [48]. At the same time, Choi et al. [49] demonstrated 
that P. gingivalis-specific helper T cell clones derived from 
mice immunized with P. gingivalis alone had a Th1 profile 
while those derived from mice immunized with F. nucleatum 
prior to P. gingivalis had a Th2 profile. The latter research 
group also reported that anti-F. nucleatum antibody elicited 
by immunization of F. nucleatum prior to P. gingivalis down 
modulated the opsonophagocytic function of anti-P. gingiva-
lis immune serum [50,51].
This observation may explain in part why the opsonophago-
cytic function of anti-P. gingivalis-specific antibodies from 
periodontal patients is impaired [52].
This immune regulating phenomenon observed with co-
infecting microorganisms within the subgingival polymicro-
bial biofilm community should be taken into consideration 
when researchers design any periodontal vaccine. The fine 
tuning of helper T-cell polarization secreting an array of char-
acteristic cytokines would obviously influence the ultimate 
outcome of any vaccine trial.
Immunization of M. fascicularis with P. gingivalis produced 
antibodies reactive not only with homologous antigens but 
also with those of B. forsythus (now called T. forsythia), a puta-
tive Gram-negative periodontopathic bacterium sharing anti-
gens within the subgingival microbial community [53].
VACCINE DESIGN VIA FINE-TUNING OF  
ANTIGEN-SPECIFIC T-CELLS IN  
PERIODONTAL DISEASE
Polarization of helper T-cells depends, in part, on the nature 
of the antigens, source of adjuvants, duration of antigenic chal-
lenge, presence of co-stimulatory molecules, and the type of 
antigen-presenting cell [54].
Periodontal disease severity is counterbalanced by the fine-
tuning of the so-called Th1/Th2 lymphocyte axis and the ar-
ray of cytokine profiles contingent on T-cell polarization and 
immunoglobulin profiles secreted by B-lymphocytes. Inter-
leukin-10 (IL-10) secreted by a number of different cell types 
is thought to exert a protective role against the progression 
of periodontal disease. This is supported by the observation 
that IL-10 knock-out mice demonstrate significantly lower 
bone levels and higher susceptibility to periodontal infection 
[55]. Care however must be taken in interpreting these results, 
as high levels of IL-10 may also stimulate IL-1 production by 
B cells and it has been suggested that the response curve to IL-
10 follows a U shape such that both low levels as well as high 
levels of IL-10 are associated with disease progression [56].
In order to study immune modulation mechanisms, Yamashi-Journal of Periodontal
& Implant Science JPIS
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ta et al. [57] adoptively transferred cloned A. actinomycetem-
comitans-specific T-helper cells into a rat model followed by 
infection with A. actinomycetemcomitans. Rats adoptively 
transferred with the A. actinomycetemcomitans-specific T-cell 
clone demonstrated a significantly lower amount of bone loss 
when compared with the control group [57]. In a following 
study, they further showed the beneficial role of the Th2 clone 
in terms of antibody production and protection from peri-
odontal bone loss [58].
In contrast, it is well established that chronic periodontitis 
is a B cell/plasma cell lesion while gingivitis is identical to de-
layed type hypersensitivity and as such is a T cell/macrophage 
lesion. In this context therefore, Gemmell and Seymour [59] 
have shown in humans that Th1-dominated lesions are asso-
ciated with stability, while Th2-dominated lesions are associ-
ated with progressive disease, such that downregulation of 
Th2 responses with a concomitant increase in Th1 responses 
selectively against the bacteria may have therapeutic effects. 
However, the polarization of P. gingivalis-specific T-cell lines 
or clones in periodontal lesions is still controversial.
Further experiments on immune modulation by pathogen-
specific T-cell clones may lead to a greater understanding of 
the specific role of antigen-specific T-lymphocytes in the 
pathogenesis of periodontal disease at the species level. It 
could also pave the way to the development of an adequate 
protection strategy against pathogenic agents. At this stage, 
however, it would appear that it is the balance between Th1 
and Th2 cytokines that plays an important role in maintain-
ing alveolar bone homeostasis [59,60].
Therefore, more refined mechanisms may have to be inves-
tigated using adoptive transfer of T-cell subsets specific to the 
more defined antigens interest for a vaccine before the spe-
cific vaccines can be fully developed. As an innovative strate-
gy, vaccines designed to stimulate antigen-specific regulato-
ry T-cells (Tregs, CD4+, CD25+, FoxP3+), secreting IL-10 and 
tumor necrosis factor beta (TGF-β), may provide new clues to 
periodontal disease prevention, through the induction of ei-
ther immune tolerance or effector function [61].
DEVELOPMENT STRATEGIES FOR A VACCINE 
AGAINST PERIODONTITIS AS A POLYMICRO-
BIAL INFECTION
Most periodontal immunization studies have targeted a 
single pathogenic species. However, a number of the poten-
tial candidate antigenic determinants may share a sequence 
homology with other periodontopathic bacteria. These anti-
gens may include phosphorylcholine [62], CPS [63], and heat-
shock protein (HSP) [64,65]. Phosphorylcholine, however, would 
not be a suitable candidate antigen as it has not been identi-
fied in P. gingivalis. In addition, CPS is not a potent inducer 
of T-cell-mediated immunity and would require protein con-
jugation in any vaccine design [22]. Therefore HSP antigen, 
which has been identified in most putative periodontal patho-
genic bacteria with a high level of sequence homology, may 
be a suitable candidate molecule. 
The notion that periodontal disease is a polymicrobial in-
fection prompted a study in which rats were immunized with 
P. gingivalis HSP60. Alveolar bone loss was experimentally 
induced by infection with multiple periodontopathogenic 
bacteria. Significantly high levels of anti-P. gingivalis HSP 
IgG antibody were elicited and there was a substantial reduc-
tion in alveolar bone loss induced by either P. gingivalis or by 
multiple bacterial infections [66]. This study postulated that P. 
gingivalis HSP60 could potentially be developed as a vaccine 
to inhibit periodontal disease induced by multiple pathogen-
ic bacteria [67]. These results may well pave a new way in the 
development of periodontal vaccines targeting the mixed mi-
crobial component. Moreover, conjugating the cross-reactive 
HSP60 with CPSs may also be a potential versatile vaccine in 
the future. Interestingly, patients whose sera recognized both 
P. gingivalis HSP peptide number 19 and cross-reactive hu-
man HSP peptide number 19 have demonstrated a signifi-
cantly higher level of alveolar bone, strongly suggesting an 
immune-modulating role for the cross-reactive peptide num-
ber 19 in periodontitis [45,68].
DEVELOPMENT STRATEGY FOR A VACCINE 
AGAINST PERIODONTITIS-TRIGGERED  
SYSTEMIC DISEASES
A number of different mechanisms have been postulated 
to explain the link between periodontal disease and athero-
sclerosis. In particular, increased systemic inflammation, with 
elevated inflammatory biomarkers, in periodontal patients 
may contribute to the perpetuation of atherosclerotic cardio-
vascular disease [69]. Furthermore, it has been suggested that 
the microbial components responsible for periodontal infec-
tion may trigger the development of autoimmune disease. 
Most recently, HSP of P. gingivalis has been a molecule of con-
siderable interest since it may be a candidate trigger molecule 
linking infectious disease (e.g. periodontitis) and systemic au-
toimmune diseases, such as atherosclerosis, diabetes mellitus, 
and rheumatoid arthritis [70-73].
Recently, Choi et al. [74-78] have mapped the immunodom-
inant T- and B-cell epitopes of P. gingivalis HSP60 in peri-
odontitis and atherosclerosis patients. Furthermore, they have 
cloned hybridomas producing anti-P. gingivalis HSP60 mono-
clonal antibodies with either mono-reactivity to homologous 
HSP60 or poly-reactivity to multiple bacterial HSP’s and mam-Journal of Periodontal
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malian HSP60. The poly-reactive monoclonal antibody rec-
ognized peptide number 19 (TLVVNRLRGSLKICAVKAPG) of 
37 synthetic peptides spanning the whole molecule of P. gin-
givalis HSP60 [46,79]. This novel finding could provide a clue 
to identifying a possible candidate peptide epitope that could 
be further develop into periodontal disease-systemic autoim-
mune diseases (i.e. atherosclerosis, diabetes mellitus, or rheu-
matoid arthritis) vaccine. Such a vaccine might be useful in 
multifactorial diseases such as atherosclerosis and diabetes, 
where human HSP may be a critical target molecule in auto-
immunity triggered by exogenous bacterial HSP. P. gingivalis 
HSP peptide number 19 was recognized by all the sera from 
atherosclerosis patients, strongly supporting the role of mo-
lecular mimicry in the periodontal-atherosclerosis link [46,79]. 
The basic tenet of the hypothesis is that peptide number 19 
may stimulate specific CD4+, CD25+, and FoxP3+ regulatory 
T-cells, which may in turn suppress the development of au-
toimmune diseases. This hypothesis is being investigated; 
however, care must be taken to ensure that any vaccine based 
on this concept does not itself trigger an autoimmune re-
sponse. Interestingly, as mentioned above, patients whose sera 
recognized both P. gingivalis HSP peptide number 19 and hu-
man HSP peptide #19 have demonstrated a significantly high-
er level of alveolar bone, strongly suggesting an immune-mod-
ulating role for the cross-reactive peptide number 19 in peri-
odontitis [68]. The fact that all atherosclerosis patients also 
exhibited antibodies to peptide number 19, however, sug-
gests that it may be also involved in the pathogenesis of ath-
erosclerosis.
DEVELOPING THE ADVANCED TOOLS FOR 
ENHANCING VACCINE EFFICACY
Recently, a variety of strategies to enhance the immunoge-
nicity of antigenic components of B- or T-lymphocytes have 
been adopted in vaccine trials against periodontal disease. 
These include, but not limited to, immunization of dendritic 
cells pulsed with antigens, the use of improved adjuvant for-
mulas (e.g. the use of alum as an alternative to HSP-based ad-
juvant), the use of recombinant plant monoclonal antibodies 
(plantibodies) [80,81], and the use of transgenic microorgan-
isms as antigen vectors [82,83]. These attempts leave challeng-
ing areas to be pursued further in the quest for a more so-
phisticated design that may guarantee the efficacy and safety 
of prolonged immune memory. 
LESSONS FROM THE PAST FOR THE FUTURE
As yet, there are no periodontal vaccine trials that have been 
successful in satisfying all requirements; to prevent the colo-
nization of multiple pathogen biofilm in the subgingival area, 
to elicit a high level of effector molecules such as immuno-
globulin sufficient to opsonize and phagocytose the invading 
organisms, to suppress alveolar bone loss, and to stimulate 
helper T-cell polarization that exerts cytokine functions opti-
mal for protection against bacteria and tissue destruction.
As an innovative strategy, vaccines using cross-reactive im-
munodominant epitopes as antigenic molecules in an attempt 
to stimulate antigen-specific regulatory T-cells (Tregs, CD4+, 
CD25+, FoxP3+), secreting IL-10 and TGF-β, may provide new 
clues for periodontal disease prevention, through the induc-
tion of either immune tolerance or an effector function. 
Periodontal disease as a multifactorial and polymicrobial 
disease requires a sophisticated vaccine design regimen tar-
geting multiple pathogenic species. Vaccine regimens includ-
ing the commonly shared antigens by selected periodonto-
pathogenic species would be considered an innovative strat-
egy.
Traditional periodontal vaccine trials aim to stimulate the 
immune system to produce increased levels of immunoglob-
ulin of desired specificity. To accomplish this end, a conjugate 
vaccine (i.e. protein-CPS conjugate), dendritic-cell based im-
munotherapy, and subunit DNA vaccine encoding the desired 
immunogenic epitope have been devised.
Animal models for vaccine trials may pose discrepancies 
with human models in major histocompatibility complex-re-
striction of antigens presented by antigen presenting, thus 
obscuring the immunodominant epitope(s). A humanized 
mouse system has been proposed that has been reconstitut-
ed with human PBLs. This system needs to meet the require-
ment of least leakiness of a mouse immune system. More 
recently, a genetically engineered mouse system, such as the 
NOD.CB17-prkdc
scid/J mouse, has been introduced for the 
study of infectious and autoimmune diseases in humans. This 
model may also prove useful for the study of periodontal dis-
ease and putative periodontal vaccines.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
ACKNOWLEDGMENTS
The authors wish to express their appreciation to Professor 
Katsuji Okuda, Tokyo Dental College, Japan, for his construc-
tive comments. The manuscript has been supported in part 
by grants from the Korea Healthcare Technology R&D Proj-
ect, Ministry of Health & Welfare, Republic of Korea A080391, 
KOSEF RO1-2008-000-20044-0, and KRF E00130.Journal of Periodontal
& Implant Science JPIS
Vaccines against periodontitis: a forward-looking review 160
REFERENCES
1.  Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL 
Jr. Microbial complexes in subgingival plaque. J Clin Peri-
odontol 1998;25:134-44.
2. Slots J. Systemic antibiotics in periodontics. J Periodontol 
2004;75:1553-65.
3. Parra B, Slots J. Detection of human viruses in periodontal 
pockets using polymerase chain reaction. Oral Microbiol 
Immunol 1996;11:289-93.
4. Contreras A, Umeda M, Chen C, Bakker I, Morrison JL, Slots 
J. Relationship between herpesviruses and adult periodonti-
tis and periodontopathic bacteria. J Periodontol 1999;70: 
478-84.
5.  Kubar A, Saygun I, Yapar M, Ozdemir A, Slots J. Real-time 
PCR quantification of cytomegalovirus in aggressive peri-
odontitis lesions using TaqMan technology. J Periodontal 
Res 2004;39:81-6.
6. Ling LJ, Ho CC, Wu CY, Chen YT, Hung SL. Association 
between human herpesviruses and the severity of peri-
odontitis. J Periodontol 2004;75:1479-85.
7.  Dzink JL, Socransky SS, Haffajee AD. The predominant 
cultivable microbiota of active and inactive lesions of de-
structive periodontal diseases. J Clin Periodontol 1988;15: 
316-23.
8. Sundqvist G. Pathogenicity and virulence of black-pigment-
ed gram-negative anaerobes. FEMS Immunol Med Micro-
biol 1993;6:125-37.
9. Persson GR, Engel D, Whitney C, Darveau R, Weinberg A, 
Brunsvold M, et al. Immunization against Porphyromon-
as gingivalis inhibits progression of experimental periodon-
titis in nonhuman primates. Infect Immun 1994;62:1026-31.
10. Houston LS, Lukehart SA, Persson GR, Page RC. Function 
of anti-Porphyromonas gingivalis immunoglobulin class-
es in immunized Macaca fascicularis. Oral Microbiol Im-
munol 1999;14:86-91.
11.  Page RC. Vaccination and periodontitis: myth or reality. J 
Int Acad Periodontol 2000;2:31-43.
12. Gibson FC 3rd, Gonzalez DA, Wong J, Genco CA. Porphy-
romonas gingivalis-specific immunoglobulin G prevents 
P. gingivalis-elicited oral bone loss in a murine model. In-
fect Immun 2004;72:2408-11.
13. Travis J, Pike R, Imamura T, Potempa J. Porphyromonas 
gingivalis proteinases as virulence factors in the develop-
ment of periodontitis. J Periodontal Res 1997;32:120-5.
14. Kadowaki T, Yoneda M, Okamoto K, Maeda K, Yamamoto 
K. Purification and characterization of a novel arginine-
specific cysteine proteinase (argingipain) involved in the 
pathogenesis of periodontal disease from the culture su-
pernatant of Porphyromonas gingivalis. J Biol Chem 1994; 
269:21371-8.
15.  Imamura T. The role of gingipains in the pathogenesis of 
periodontal disease. J Periodontol 2003;74:111-8.
16. Moritz AJ, Cappelli D, Lantz MS, Holt SC, Ebersole JL. Im-
munization with Porphyromonas gingivalis cysteine pro-
tease: effects on experimental gingivitis and ligature-in-
duced periodontitis in Macaca fascicularis. J Periodontol 
1998;69:686-97.
17.  Gibson FC 3rd, Genco CA. Prevention of Porphyromonas 
gingivalis-induced oral bone loss following immuniza-
tion with gingipain R1. Infect Immun 2001;69:7959-63.
18. Inagaki S, Ishihara K, Yasaki Y, Yamada S, Okuda K. Anti-
body responses of periodontitis patients to gingipains of 
Porphyromonas gingivalis. J Periodontol 2003;74:1432-9.
19. Kuboniwa M, Amano A, Shizukuishi S, Nakagawa I, Hama-
da S. Specific antibodies to Porphyromonas gingivalis Lys-
gingipain by DNA vaccination inhibit bacterial binding to 
hemoglobin and protect mice from infection. Infect Immun 
2001;69:2972-9.
20. Evans RT, Klausen B, Sojar HT, Bedi GS, Sfintescu C, Rama-
murthy NS, et al. Immunization with Porphyromonas (Bac-
teroides) gingivalis fimbriae protects against periodontal 
destruction. Infect Immun 1992;60:2926-35.
21. Fan Q, Sims T, Sojar H, Genco R, Page RC. Fimbriae of 
Porphyromonas gingivalis induce opsonic antibodies that 
significantly enhance phagocytosis and killing by human 
polymorphonuclear leukocytes. Oral Microbiol Immunol 
2001;16:144-52.
22. Choi JI, Schifferle RE, Yoshimura F, Kim BW. Capsular poly-
saccharide-fimbrial protein conjugate vaccine protects 
against Porphyromonas gingivalis infection in SCID mice 
reconstituted with human peripheral blood lymphocytes. 
Infect Immun 1998;66:391-3.
23. Gonzalez D, Tzianabos AO, Genco CA, Gibson FC 3rd. Im-
munization with Porphyromonas gingivalis capsular poly-
saccharide prevents P. gingivalis-elicited oral bone loss in 
a murine model. Infect Immun 2003;71:2283-7.
24. Takazoe I, Nakamura T, Okuda K. Colonization of the sub-
gingival area by Bacteroides gingivalis. J Dent Res 1984;63: 
422-6.
25. Slots J, Gibbons RJ. Attachment of Bacteroides melanino-
genicus subsp. asaccharolyticus to oral surfaces and its pos-
sible role in colonization of the mouth and of periodontal 
pockets. Infect Immun 1978;19:254-64.
26. Mouton C, Bouchard D, Deslauriers M, Lamonde L. Im-
munochemical identification and preliminary character-
ization of a nonfimbrial hemagglutinating adhesin of Bac-
teroides gingivalis. Infect Immun 1989;57:566-73.
27. Maeba S, Otake S, Namikoshi J, Shibata Y, Hayakawa M, 
Abiko Y, et al. Transcutaneous immunization with a 40-kDa Journal of Periodontal
& Implant Science JPIS
Jeom-Il Choi et al. 161
outer membrane protein of Porphyromonas gingivalis 
induces specific antibodies which inhibit coaggregation 
by P. gingivalis. Vaccine 2005;23:2513-21.
28. Saito S, Hiratsuka K, Hayakawa M, Takiguchi H, Abiko Y. 
Inhibition of a Porphyromonas gingivalis colonizing fac-
tor between Actinomyces viscosus ATCC 19246 by mono-
clonal antibodies against recombinant 40-kDa outer-mem-
brane protein. Gen Pharmacol 1997;28:675-80.
29. Abiko Y, Ogura N, Matsuda U, Yanagi K, Takiguchi H. A 
human monoclonal antibody which inhibits the coaggre-
gation activity of Porphyromonas gingivalis. Infect Immun 
1997;65:3966-9.
30. Ross BC, Czajkowski L, Hocking D, Margetts M, Webb E, 
Rothel L, et al. Identification of vaccine candidate antigens 
from a genomic analysis of Porphyromonas gingivalis. 
Vaccine 2001;19:4135-42.
31. Chu L, Bramanti TE, Ebersole JL, Holt SC. Hemolytic ac-
tivity in the periodontopathogen Porphyromonas gingi-
valis: kinetics of enzyme release and localization. Infect 
Immun 1991;59:1932-40.
32. Okuda K, Kato T, Naito Y, Takazoe I, Kikuchi Y, Nakamura 
T, et al. Protective efficacy of active and passive immuni-
zations against experimental infection with Bacteroides 
gingivalis in ligated hamsters. J Dent Res 1988;67:807-11.
33. Booth V, Ashley FP, Lehner T. Passive immunization with 
monoclonal antibodies against Porphyromonas gingiva-
lis in patients with periodontitis. Infect Immun 1996;64: 
422-7.
34. Booth V, Lehner T. Characterization of the Porphyromon-
as gingivalis antigen recognized by a monoclonal antibody 
which prevents colonization by the organism. J Periodon-
tal Res 1997;32:54-60.
35. Shibata Y, Kurihara K, Takiguchi H, Abiko Y. Construction 
of a functional single-chain variable fragment antibody 
against hemagglutinin from Porphyromonas gingivalis. 
Infect Immun 1998;66:2207-12.
36. Hosogi Y, Hayakawa M, Abiko Y. Monoclonal antibody 
against Porphyromonas gingivalis hemagglutinin inhib-
its hemolytic activity. Eur J Oral Sci 2001;109:109-13.
37.  Kaizuka K, Hosogi Y, Hayakawa M, Shibata Y, Abiko Y. Hu-
man monoclonal antibody inhibits Porphyromonas gin-
givalis hemagglutinin activity. J Periodontol 2003;74:38-43.
38. Shibata Y, Hosogi Y, Hayakawa M, Hori N, Kamada M, 
Abiko Y. Construction of novel human monoclonal anti-
bodies neutralizing Porphyromonas gingivalis hemagglu-
tination activity using transgenic mice expressing human 
Ig loci. Vaccine 2005;23:3850-6.
39. Harano K, Yamanaka A, Okuda K. An antiserum to a syn-
thetic fimbrial peptide of Actinobacillus actinomycetem-
comitans blocked adhesion of the microorganism. FEMS 
Microbiol Lett 1995;130:279-85.
40. Takamatsu-Matsushita N, Yamaguchi N, Kawasaki M, 
Yamashita Y, Takehara T, Koga T. Immunogenicity of Acti-
nobacillus actinomycetemcomitans serotype b-specific 
polysaccharide-protein conjugate. Oral Microbiol Immu-
nol 1996;11:220-5.
41. Herminajeng E, Asmara W, Yuswanto A, Barid I, Sosrose-
no W. Protective humoral immunity induced by surface-
associated material from Actinobacillus actinomycetem-
comitans in mice. Microbes Infect 2001;3:997-1003.
42. Shao H, Demuth DR. Quorum sensing regulation of bio-
film growth and gene expression by oral bacteria and peri-
odontal pathogens. Periodontol 2000 2010;52:53-67.
43. Kuboniwa M, Lamont RJ. Subgingival biofilm formation. 
Periodontol 2000 2010;52:38-52.
44. Lee J, Suh J, Choi J. B-1 cell-derived monoclonal antibodies 
and costimulatory molecules. J Surg Res 2009;154:293-8.
45. Choi JI, Kim SJ, Lee JY, Lee JY. Production and character-
ization of cross-reactive anti-Porphyromonas gingivalis 
heat shock protein 60 monoclonal antibody. J Korean Acad 
Periodontol 2008;38:565-78.
46. Ha JA, Choi JI. Monoclonal antibody to Porphyromonas 
gingivalis heat-shock protein (Abstract 2631). 88th General 
Session & Exhibition of the IADR; 2010 Jul 14-17; Barcelo-
na, Spain. Barcelona: International Association for Dental 
Research; 2010.
47. Notkins AL. Polyreactive antibodies and polyreactive anti-
gen-binding B (PAB) Cells. Curr Top Microbiol Immunol 
2000;252:241-9.
48. Gemmell E, Bird PS, Ford PJ, Ashman RB, Gosling P, Hu Y, 
et al. Modulation of the antibody response by Porphyromo-
nas gingivalis and Fusobacterium nucleatum in a mouse 
model. Oral Microbiol Immunol 2004;19:247-51.
49. Choi JI, Borrello MA, Smith ES, Zauderer M. Polarization 
of Porphyromonas gingivalis-specific helper T-cell subsets 
by prior immunization with Fusobacterium nucleatum. 
Oral Microbiol Immunol 2000;15:181-7.
50. Choi J, Borrello MA, Smith E, Cutler CW, Sojar H, Zauder-
er M. Prior exposure of mice to Fusobacterium nucleatum 
modulates host response to Porphyromonas gingivalis. 
Oral Microbiol Immunol 2001;16:338-44.
51.  Choi JI, Kim US, Kim SJ, Son WS, Park HR. Fusobacterium 
nucleatum impairs serum binding to Porphyromonas gin-
givalis biofilm. Oral Microbiol Immunol 2003;18:92-4.
52. Sjostrom K, Darveau R, Page R, Whitney C, Engel D. Op-
sonic antibody activity against Actinobacillus actinomy-
cetemcomitans in patients with rapidly progressive peri-
odontitis. Infect Immun 1992;60:4819-25.
53. Vasel D, Sims TJ, Bainbridge B, Houston L, Darveau R, Page 
RC. Shared antigens of Porphyromonas gingivalis and Bac-Journal of Periodontal
& Implant Science JPIS
Vaccines against periodontitis: a forward-looking review 162
teroides forsythus. Oral Microbiol Immunol 1996;11:226-35.
54. Seymour GJ, Taylor JJ. Shouts and whispers: an introduc-
tion to immunoregulation in periodontal disease. Periodon-
tol 2000 2004;35:9-13.
55.  Sasaki H, Okamatsu Y, Kawai T, Kent R, Taubman M, Stash-
enko P. The interleukin-10 knockout mouse is highly sus-
ceptible to Porphyromonas gingivalis-induced alveolar 
bone loss. J Periodontal Res 2004;39:432-41.
56. Cullinan MP, Westerman B, Hamlet SM, Palmer JE, Faddy 
MJ, Seymour GJ, et al. Progression of periodontal disease 
and interleukin-10 gene polymorphism. J Periodontal Res 
2008;43:328-33.
57.  Yamashita K, Eastcott JW, Taubman MA, Smith DJ, Cox DS. 
Effect of adoptive transfer of cloned Actinobacillus actino-
mycetemcomitans-specific T helper cells on periodontal 
disease. Infect Immun 1991;59:1529-34.
58. Eastcott JW, Yamashita K, Taubman MA, Harada Y, Smith 
DJ. Adoptive transfer of cloned T helper cells ameliorates 
periodontal disease in nude rats. Oral Microbiol Immunol 
1994;9:284-9.
59. Gemmell E, Seymour GJ. Immunoregulatory control of 
Th1/Th2 cytokine profiles in periodontal disease. Periodon-
tol 2000 2004;35:21-41.
60. Alayan J, Ivanovski S, Farah CS. Alveolar bone loss in T help-
er 1/T helper 2 cytokine-deficient mice. J Periodontal Res 
2007;42:97-103.
61. Belkaid Y. Regulatory T cells and infection: a dangerous 
necessity. Nat Rev Immunol 2007;7:875-88.
62. Gmur R, Thurnheer T, Guggenheim B. Dominant cross-
reactive antibodies generated during the response to a va-
riety of oral bacterial species detect phosphorylcholine. J 
Dent Res 1999;78:77-85.
63. Laine ML, Appelmelk BJ, van Winkelhoff AJ. Prevalence and 
distribution of six capsular serotypes of Porphyromonas 
gingivalis in periodontitis patients. J Dent Res 1997;76:1840-4.
64. Hinode D, Nakamura R, Grenier D, Mayrand D. Cross-re-
activity of specific antibodies directed to heat shock pro-
teins from periodontopathogenic bacteria and of human 
origin [corrected]. Oral Microbiol Immunol 1998;13:55-8.
65. Maeda H, Miyamoto M, Hongyo H, Nagai A, Kurihara H, 
Murayama Y. Heat shock protein 60 (GroEL) from Porphy-
romonas gingivalis: molecular cloning and sequence anal-
ysis of its gene and purification of the recombinant pro-
tein. FEMS Microbiol Lett 1994;119:129-35.
66. Lee JY, Yi NN, Kim US, Choi JS, Kim SJ, Choi JI. Porphyromo-
nas gingivalis heat shock protein vaccine reduces the al-
veolar bone loss induced by multiple periodontopatho-
genic bacteria. J Periodontal Res 2006;41:10-4.
67. Choi JI, Choi KS, Yi NN, Kim US, Choi JS, Kim SJ. Recogni-
tion and phagocytosis of multiple periodontopathogenic 
bacteria by anti-Porphyromonas gingivalis heat-shock 
protein 60 antisera. Oral Microbiol Immunol 2005;20:51-5.
68. Park CS, Lee JY, Kim SJ, Choi JI. Identification of immuno-
logical parameters associated with the alveolar bone level 
in periodontal patients. J Periodontal Implant Sci 2010;40: 
61-8.
69. Friedewald VE, Kornman KS, Beck JD, Genco R, Goldfine 
A, Libby P, et al. The American Journal of Cardiology and 
Journal of Periodontology editors’ consensus: periodonti-
tis and atherosclerotic cardiovascular disease. J Periodon-
tol 2009;80:1021-32.
70. Van Eden W, Wick G, Albani S, Cohen I. Stress, heat shock 
proteins, and autoimmunity: how immune responses to 
heat shock proteins are to be used for the control of chronic 
inflammatory diseases. Ann N Y Acad Sci 2007;1113:217-37.
71.  Van Eden W, Van der Zee R, Prakken B. Heat-shock proteins 
induce T-cell regulation of chronic inflammation. Nat Rev 
Immunol 2005;5:318-30.
72. Hansson GK, Libby P. The immune response in atheroscle-
rosis: a double-edged sword. Nat Rev Immunol 2006;6:508-
19.
73. Rajaiah R, Moudgil KD. Heat-shock proteins can promote 
as well as regulate autoimmunity. Autoimmun Rev 2009;8: 
388-93.
74. Choi JI, Chung SW, Kang HS, Rhim BY, Kim SJ. Establish-
ment of Porphyromonas gingivalis heat-shock-protein-
specific T-cell lines from atherosclerosis patients. J Dent 
Res 2002;81:344-8.
75.  Choi JI, Chung SW, Kang HS, Rhim BY, Park YM, Kim US, 
et al. Epitope mapping of Porphyromonas gingivalis heat-
shock protein and human heat-shock protein in human 
atherosclerosis. J Dent Res 2004;83:936-40.
76. Choi J, Chung SW, Kim SJ. Establishment of Porphyromo-
nas gingivalis-specific T-cell lines from atherosclerosis pa-
tients. Oral Microbiol Immunol 2001;16:316-8.
77.  Choi JI, Kang HS, Park YM, Kim SJ, Kim US. Identification 
of T-cell epitopes of Porphyromonas gingivalis heat-shock-
protein 60 in periodontitis. Oral Microbiol Immunol 2004; 
19:1-5.
78. Bak JG, kim SJ, Choi JI. Epitope specificity of Porphyromo-
nas gingivalis heat shock protein for T-cell and/or B-cell 
in human atherosclerosis. J Korean Acad Periodontol 2003; 
33:179-91.
79. Choi JI, Chung SW, Lee SY, Kim KH, Choi BK. Immunore-
activity of poly-specific peptide from Porphyromonas gin-
givalis heat shock protein (Abstract 2716). 88th General Ses-
sion & Exhibition of the IADR; 2010 Jul 14-17; Barcelona, 
Spain. Barcelona: International Association for Dental Re-
search; 2010.
80. Ma JK, Hiatt A, Hein M, Vine ND, Wang F, Stabila P, et al. Journal of Periodontal
& Implant Science JPIS
Jeom-Il Choi et al. 163
Generation and assembly of secretory antibodies in plants. 
Science 1995;268:716-9.
81. Shin EA, Lee JY, Kim TG, Park YK, Langridge WH. Synthe-
sis and assembly of an adjuvanted Porphyromonas gingi-
valis fimbrial antigen fusion protein in plants. Protein Expr 
Purif 2006;47:99-109.
82. Sharma A, Sojar HT, Hruby DE, Kuramitsu HK, Genco RJ. 
Secretion of Porphyromonas gingivalis fimbrillin polypep-
tides by recombinant Streptococcus gordonii. Biochem 
Biophys Res Commun 1997;238:313-6.
83. Sharma A, Honma K, Evans RT, Hruby DE, Genco RJ. Oral 
immunization with recombinant Streptococcus gordonii 
expressing porphyromonas gingivalis FimA domains. In-
fect Immun 2001;69:2928-34.